Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Glutamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.74 |
| ▸ | BLM | P54132 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.70 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | GRM8 | O00222 | 1/20 | 0.50 |
| ▸ | GRM6 | O15303 | 1/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.50 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glutamine SCHEMBL19743900 | 1.00 | GSR (0.74) | GSRBLMKMT2AALOX15PMP22 | |
| Glutamine SCHEMBL5461649 | 0.98 | GSR (0.77) | GSRBLMKMT2AALOX15PMP22 | |
| Glutamine SCHEMBL28030897 | 0.98 | GSR (0.77) | GSRBLMKMT2AALOX15PMP22 | |
| Glutamine SCHEMBL1812362 | 0.98 | GSR (0.77) | GSRBLMKMT2AALOX15PMP22 | |
| Glutamine SCHEMBL1347541 | 0.98 | GSR (0.77) | GSRBLMKMT2AALOX15PMP22 | |
| Glutamine SCHEMBL12468749 | 0.98 | GSR (0.77) | GSRBLMKMT2AALOX15PMP22 | |
| Glutamine SCHEMBL2143276 | 0.98 | GSR (0.77) | GSRBLMKMT2AALOX15PMP22 | |
| Glutamine SCHEMBL14485689 | 0.96 | GSR (0.74) | GSRBLMKMT2AALOX15PMP22 | |
| Glutamine SCHEMBL29022151 | 0.96 | GSR (0.74) | GSRBLMKMT2AALOX15PMP22 | |
| Glutamine SCHEMBL29022149 | 0.96 | GSR (0.74) | GSRBLMKMT2AALOX15PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3475311-B1 | MODIFIED DEXTRAN CONJUGATES COMPRISING A LYSINE-UREA-GLUTAMATE PHARMACOPHORE | DEXTECH MEDICAL AB (SE) | 2020-05-13 | — | — | EP | claimed |
| US-20190175767-A1 | MODIFIED DEXTRAN CONJUGATES COMPRISING A LYSINE-UREA-GLUTAMATE PHARMACOPHORE | DEXTECH MEDICAL AB (SE) | 2019-06-13 | — | — | US | claimed |
| EP-3475311-A1 | MODIFIED DEXTRAN CONJUGATES COMPRISING A LYSINE-UREA-GLUTAMATE PHARMACOPHORE | Dextech Medical AB (SE) | 2019-05-01 | — | — | EP | claimed |
| CN-109312004-A | Include lysine-urea-glutamic acid pharmacophore modified dextrans conjugate | 德克斯特克医疗公司 | 2019-02-05 | — | — | CN | claimed |
| WO-2017220488-A1 | MODIFIED DEXTRAN CONJUGATES COMPRISING A LYSINE-UREA-GLUTAMATE PHARMACOPHORE | DEXTECH MEDICAL AB (SE) | 2017-12-28 | — | — | WO | claimed |
| US-11931431-B2 | PSMA-targeted radiopharmaceutical for diagnosing and treating prostate cancer | FUTURECHEM CO., LTD (KR) | 2024-03-19 | — | — | US | disclosed |
| US-11931431-B2 | PSMA-targeted radiopharmaceutical for diagnosing and treating prostate cancer | FUTURECHEM CO., LTD (KR) | 2024-03-19 | — | — | US | disclosed |
| CN-112004812-B | PSMA-targeted radiopharmaceuticals for diagnosis and treatment of prostate cancer | 未来化学株式会社 | 2023-05-26 | — | — | CN | disclosed |
| CN-112004812-B | PSMA-targeted radiopharmaceuticals for diagnosis and treatment of prostate cancer | 未来化学株式会社 | 2023-05-26 | — | — | CN | disclosed |
| EP-3778592-B1 | PSMA-TARGETED RADIOPHARMACEUTICAL FOR DIAGNOSING AND TREATING PROSTATE CANCER | FUTURECHEM CO LTD (KR) | 2023-04-26 | — | — | EP | disclosed |
| US-20210106701-A1 | PSMA-TARGETED RADIOPHARMACEUTICAL FOR DIAGNOSING AND TREATING PROSTATE CANCER | FUTURECHEM CO., LTD (KR) | 2021-04-15 | — | — | US | disclosed |
| US-20210106701-A1 | PSMA-TARGETED RADIOPHARMACEUTICAL FOR DIAGNOSING AND TREATING PROSTATE CANCER | FUTURECHEM CO., LTD (KR) | 2021-04-15 | — | — | US | disclosed |
| CN-112004812-A | PSMA-targeted radiopharmaceuticals for diagnosis and treatment of prostate cancer | 未来化学株式会社 | 2020-11-27 | — | — | CN | disclosed |
| EP-3475311-B1 | MODIFIED DEXTRAN CONJUGATES COMPRISING A LYSINE-UREA-GLUTAMATE PHARMACOPHORE | DEXTECH MEDICAL AB (SE) | 2020-05-13 | — | — | EP | disclosed |
| WO-2019190266-A1 | PSMA-TARGETED RADIOPHARMACEUTICAL FOR DIAGNOSING AND TREATING PROSTATE CANCER | (주)퓨쳐켐 | 2019-10-03 | — | — | WO | disclosed |
| WO-2019190266-A1 | PSMA-TARGETED RADIOPHARMACEUTICAL FOR DIAGNOSING AND TREATING PROSTATE CANCER | (주)퓨쳐켐 | 2019-10-03 | — | — | WO | disclosed |
| US-20190175767-A1 | MODIFIED DEXTRAN CONJUGATES COMPRISING A LYSINE-UREA-GLUTAMATE PHARMACOPHORE | DEXTECH MEDICAL AB (SE) | 2019-06-13 | — | — | US | disclosed |
| EP-3475311-A1 | MODIFIED DEXTRAN CONJUGATES COMPRISING A LYSINE-UREA-GLUTAMATE PHARMACOPHORE | Dextech Medical AB (SE) | 2019-05-01 | — | — | EP | disclosed |
| CN-109312004-A | Include lysine-urea-glutamic acid pharmacophore modified dextrans conjugate | 德克斯特克医疗公司 | 2019-02-05 | — | — | CN | disclosed |
| WO-2017220488-A1 | MODIFIED DEXTRAN CONJUGATES COMPRISING A LYSINE-UREA-GLUTAMATE PHARMACOPHORE | DEXTECH MEDICAL AB (SE) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11931431-B2 | PSMA-targeted radiopharmaceutical for diagnosing and treating prostate cancer | FOLH1, PSMA1, KLK3 | GSR 2402/4885BLM 4476/4885KMT2A 931/4885 |
| US-20210106701-A1 | PSMA-TARGETED RADIOPHARMACEUTICAL FOR DIAGNOSING AND TREATING PROSTATE CANCER | FOLH1, PSMA1, KLK3 | GSR 2402/4885BLM 4476/4885KMT2A 931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.